New hope for Hard-to-Treat breast cancer: targeted combo enters final testing
NCT ID NCT07393321
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether adding the experimental drug NTQ1062 to standard hormone therapy (fulvestrant) can slow or stop the growth of advanced HR+/HER2- breast cancer in people whose cancer has returned or worsened after hormone therapy. The study includes 210 adults with specific genetic changes (PIK3CA/AKT1/PTEN). Participants will receive either NTQ1062 plus fulvestrant or a placebo plus fulvestrant, and researchers will track how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NTQ1062 (an AKT inhibitor) combined with fulvestrant
- What this could lead to
- If successful, this combination could offer a new treatment option for people with a specific genetic subtype of advanced breast cancer that has stopped responding to hormone therapy.
- What could go wrong
- This is an early-stage Phase 3 trial with only 210 participants, so results may not apply to everyone. The drug may not improve survival or could cause side effects like those seen with other AKT inhibitors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR POSITIVE/HER2 NEGATIVE ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.